SLC5A2 and diabetic kidney disease: Current treatments for DKD focuses on anti-hypertensive therapies including angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptors blockers (ARBs), strict glycemic control with anti-diabetic agents such a metformin and more recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors4,5.